Five commonly used markers (p53, TTF1, CK7, CK20, and CK34βE12) are of no use in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray extension study
| Autor: | Chiew Loon Koo, Alexandra Ruan, Yeu Sheng Tyan, Chih Ping Han, Ya Wen Cheng, Lai Fong Kok, Po Hui Wang, Ming-Yung Lee, Tina S. Wu |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Pathology
medicine.medical_specialty medicine.drug_class Uterine Cervical Neoplasms Keratin-20 Diagnostic dilemma Adenocarcinoma Monoclonal antibody Statistics Nonparametric Biomarkers Tumor medicine Humans Retrospective Studies Site of origin Tissue microarray business.industry Extension study Keratin-7 Antibodies Monoclonal Obstetrics and Gynecology General Medicine Immunohistochemistry Endometrial Neoplasms DNA-Binding Proteins Female Tumor Suppressor Protein p53 business Transcription Factors |
| Zdroj: | Archives of Gynecology and Obstetrics. 281:317-323 |
| ISSN: | 1432-0711 0932-0067 |
| DOI: | 10.1007/s00404-009-1115-z |
| Popis: | The choice of appropriate therapeutic plans for primary endocervical adenocarcinomas (ECA) and endometrial adenocarcinomas (EMA) depends on the tumor's site of origin. Some panels of antibodies help to distinguish primary ECA from EMA. However, unexpected expressions of those markers often exist, which causes this diagnostic dilemma to be still unresolved. In this study, we investigate five commonly used monoclonal antibodies (p53, TTF1, CK7, CK20, and CK34betaE12) to evaluate their potential use in distinguishing between these two gynecologic malignancies.A tissue microarray was constructed using paraffin-embedded, formalin-fixed tissues from 35 hysterectomy specimens, including 14 ECA and 21 EMA. Utilizing the avidin-biotin (ABC) technique, tissue array sections were immunostained with the five aforementioned commercially available antibodies.Immunohistochemical (IHC) expressions of p53, TTF1, CK7, CK20, and CK34betaE12 were all nonsignificant (P0.05) in frequency differences between the immunostaining results (positive vs. negative) in tumors from both the two primary adenocarcinomas (ECA vs. EMA).It is still uncertain which markers or panels would be the most appropriate for making diagnoses; hence, exploration of other useful markers, which make a definitive distinction between ECA and EMA merits further studies. This study, however, uncovered that the five commonly used monoclonal antibodies (p53, TTF1, CK7, CK20, and CK34betaE12) are of no beneficial value in distinguishing between primary ECA and EMA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink